Related Subjects:
|Basic Statistics
|Sampling in Medical Statistics
|Assessing Significance
|Reading a Medical paper
|Different Forms of Medical Trials and Studies
|Hierarchy of Evidence-Based Trials
|Bayes' Theorem
|Comparing Groups
Assessing Statistical Significance in Medical Research – Updated Feb 2026
🔍 Assessing statistical significance determines whether observed differences, associations, or effects in medical data are likely due to chance or reflect true underlying phenomena. It underpins evidence-based medicine, guiding treatment decisions, risk assessment, and policy.
Modern consensus (2026): Move beyond binary "significant/non-significant" (p < 0.05 dogma); report **effect size + 95% CI**; interpret p-values continuously; consider clinical/practical importance; correct for multiplicity; use Bayesian approaches where appropriate.
🧠 Key Concepts
- Null Hypothesis (H₀) ⚪: No effect, no difference, no association (default assumption to be tested).
- Alternative Hypothesis (H₁ or Hₐ) 🔴: There is an effect/difference/association (directional or non-directional).
- p-value 📉: Probability of observing the data (or more extreme) assuming H₀ is true.
- p < 0.05 → reject H₀ (statistically significant at α = 0.05).
- p ≥ 0.05 → fail to reject H₀ (not significant).
- Smaller p → stronger evidence against H₀ (but not "more significant").
- Significance Level (α) ⚠️: Pre-specified Type I error rate (usually 0.05; stricter 0.01 or 0.001 in genomics/large trials).
- Confidence Interval (CI) 📏: Range likely containing true population parameter (e.g., 95% CI).
- CI excluding null value (0 for difference, 1 for ratio) → significant.
- CI width reflects precision (narrower = larger sample/more precise).
📊 Common Statistical Tests for Assessing Significance
| Test | Purpose | Data Type | Key Assumptions | Effect Size | Medical Example |
|---|
| Independent t-test | Compare means (2 independent groups) | Continuous | Normality, equal variances (or Welch variant) | Cohen’s d | Mean HbA1c: metformin vs placebo |
| Paired t-test | Compare means (paired/within-subject) | Continuous | Differences normal | Cohen’s d (paired) | Pre- vs post-intervention blood pressure |
| One-way ANOVA | Compare means (3+ independent groups) | Continuous | Normality, homogeneity of variances | η² (eta-squared) | Pain scores across 3 analgesic doses |
| Chi-square (χ²) | Test association (categorical) | Categorical | Expected counts ≥5 | Cramér’s V / Phi | Response rate (yes/no) in two treatment arms |
| Fisher’s Exact | Association (small counts) | Categorical (2×2) | None (exact) | Odds ratio | Rare adverse event comparison |
| Mann-Whitney U | Compare distributions (non-parametric) | Ordinal/continuous (non-normal) | Independent samples | r = Z/√N | Non-normal quality-of-life scores |
| Wilcoxon signed-rank | Paired non-parametric | Ordinal/continuous | Paired | r | Before-after symptom severity |
| Kruskal-Wallis | 3+ groups non-parametric | Ordinal/continuous | Independent | η² (rank-based) | Multiple treatment arms, skewed data |
⚠️ Types of Errors & Power
- Type I Error (α) ❌: Reject H₀ when true (false positive). Risk = α (usually 0.05).
- Type II Error (β) ❌: Fail to reject H₀ when false (false negative). Risk = β.
- Power (1-β) ✅: Probability of detecting true effect. Target 80–90% (higher in pivotal trials).
- Power calculation factors: effect size, α, sample size, variability, one- vs two-tailed test.
📏 Interpreting p-values, CIs & Effect Sizes (2026 Best Practice)
- p-value: Continuous measure of compatibility with H₀ - not "proof" or "no effect". Avoid "trend" language; report exact p (e.g., p = 0.032, not p < 0.05).
- 95% CI: Preferred over p alone; if CI excludes null value → significant. Narrow CI = precise estimate.
- Effect Size Interpretation (Cohen guidelines, 1988; still widely used):
- Cohen’s d: 0.2 small, 0.5 medium, 0.8 large.
- η²: 0.01 small, 0.06 medium, 0.14 large.
- Cramér’s V: 0.1 small, 0.3 medium, 0.5 large.
- Clinical vs Statistical Significance: p < 0.05 but tiny effect may not be clinically meaningful (e.g., 1 mmHg BP drop).
🏥 Clinical & Research Relevance
- Clinical Trials: Significance testing for primary/secondary endpoints (e.g., superiority/non-inferiority); multiplicity adjustment (Bonferroni, Holm, FDR).
- Epidemiology: Assess risk factors (OR/RR CIs exclude 1), prevalence differences, dose-response.
- Diagnostic Accuracy: ROC AUC significance, sensitivity/specificity comparisons.
- Meta-analysis: Pooled effect significance (forest plots with CIs).
- 2026 Trends: Bayesian inference (credible intervals), equivalence testing, prediction intervals, focus on estimation over hypothesis testing.
Teaching Point 🩺
Statistical significance ≠ clinical importance.
Always report **effect size + 95% CI** (not just p-value).
p < 0.05 → evidence against H₀, but interpret magnitude & precision.
CI excludes null value → significant; width shows uncertainty.
Avoid over-reliance on p < 0.05; consider Type I/II errors, power, multiplicity, bias.
In medicine: Is the difference big enough to change practice or patient outcomes?
📚 References (Feb 2026)
- Wasserstein RL et al. Moving to a World Beyond “p < 0.05”. Am Stat 2019 (updated consensus 2026).
- Lakens D. Equivalence testing & effect sizes. Adv Methods Pract Psychol Sci 2025.
- Altman DG & Bland JM. Statistics Notes series (BMJ, ongoing 2025–2026).
- Recent: Bayesian vs frequentist in medical trials (JAMA 2026); open science reporting guidelines.
